Recent Advances in Chalcone Derivatives as Promising Antimicrobial Agents: A Mini Review

Harra Ismi Farah; Nur Masyithah Zamruddin; Dalifa Ramadhani; Sandra Amalia Riyadi

doi:10.30872/jtpc.v10i2.417

Authors

Harra Ismi Farah Universitas Mulawarman Author
Nur Masyithah Zamruddin Universitas Mulawarman Author
Dalifa Ramadhani Universitas Mulawarman Author
Sandra Amalia Riyadi Universitas Pakuan Author

DOI:

https://doi.org/10.30872/jtpc.v10i2.417

Keywords:

Chalcone, Antimicrobial, Synthetic, Antibacterial, Antifungal

Abstract

The rapid emergence of antimicrobial resistance (AMR) has created an urgent need for the development of novel antimicrobial agents with improved efficacy and reduced susceptibility to resistance. Among various bioactive scaffolds, chalcone derivatives have attracted considerable attention because of their structural diversity, synthetic accessibility, and broad-spectrum antimicrobial properties. This mini review summarizes recent advances in the biosynthesis and synthetic approaches of chalcone derivatives, highlighting their applications as promising antimicrobial agents. In addition, recent findings on the antimicrobial activities of chalcone derivatives against Gram-positive bacteria, Gram-negative bacteria, mycobacteria, and pathogenic fungi are discussed, with particular emphasis on structure–activity relationships that govern their biological performance. The review further describes the diverse mechanisms underlying their antimicrobial activity, including membrane disruption, inhibition of essential bacterial enzymes, interference with nucleic acid and protein synthesis, suppression of biofilm formation, and attenuation of bacterial virulence. Collectively, these complementary mechanisms contribute to the broad-spectrum antimicrobial activity of chalcone derivatives and provide a promising strategy for addressing antimicrobial resistance. Although substantial progress has been achieved, further studies focusing on rational structural optimization, comprehensive biological evaluation, pharmacokinetic characterization, and in vivo validation are required to facilitate the translation of chalcone derivatives into clinically relevant antimicrobial agents.

Downloads

Download data is not yet available.

References

D. C. Nwobodo, M.C. Ugwu, C. O. Anie, M. T.S. Al-Ouqaili, J. C. Ikem, U. V. Chigozie, M. Saki., “Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace,” Sep. 01, 2022, J. Clin Lab Anal, vol. 36, e24655. doi: 10.1002/jcla.24655.

[2] Z. Breijyeh, B. Jubeh, and R. Karaman, “Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it,” Mar. 02, 2020, Molecule, vol. 25, 1340. doi: 10.3390/molecules25061340.

[3] M. Terreni, M. Taccani, and M. Pregnolato, “New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives,” May 02, 2021, Molecule, vol.26, 2671. doi: 10.3390/molecules26092671.

[4] M. E. Elshobary, N. K. Badawy, Y. Ashraf, A. A. Zatioun, H. H. Masriya, M. M. Ammar, N. A. Mohamed, S. Mourad, and A. M. Assy., “Combating Antibiotic Resistance: Mechanisms, Multidrug-Resistant Pathogens, and Novel Therapeutic Approaches: An Updated Review,” Mar. 01, 2025, Pharmaceutical, vol 18, 402. doi: 10.3390/ph18030402.

[5] R. Ahsan, S. Paul, M. S. Alam, and A. F. M. M. Rahman, “Synthesis, Biological Properties, In Silico ADME, Molecular Docking Studies, and FMO Analysis of Chalcone Derivatives as Promising Antioxidant and Antimicrobial Agents,” Feb. 2025, ACS Omega, vol. 10, no. 5, pp. 4367–4387, doi: 10.1021/acsomega.4c06897.

[6] A. T. L. dos Santos, J. B. de Arujo-Neto, M. M. C. da Silva, M. E. P. da Silva, J. N. P. Carneiro, V. J. A. Fonseca, H. D. M. Coutinho, P. N. Bandeira, H. S. dos Santos, F. R. da Silva Mendes, D. L. Sales, M. F. B. Morais-Braga., “Synthesis of chalcones and their antimicrobial and drug potentiating activities,” Jul. 2023, Microb. Pathog., vol. 180, doi: 10.1016/j.micpath.2023.106129.

[7] K. Mezgebe, Y. Melaku, and E. Mulugeta, “Synthesis and Pharmacological Activities of Chalcone and Its Derivatives Bearing N-Heterocyclic Scaffolds: A Review,” Jun. 06, 2023, ACS Omega, vol 8, pp. 19194-19211. doi: 10.1021/acsomega.3c01035.

[8] H. Ur Rashid, S. Khan, Irum, A. Khan, N. Ahmad, T. Shah, and K. Khan., “Direct synthesis, characterization, in vitro and in silico studies of simple chalcones as potential antimicrobial and antileishmanial agents,” 2024, R. Soc. Open Sci., vol. 11, no. 6. doi:10.1098/rsos.240410.

[9] R. Arif, M. Rana, S. Yasmeen, Amaduddin, M. Khan, M. Abid, and Rhisuddin., “Facile synthesis of chalcone derivatives as antibacterial agents: Synthesis, DNA binding, molecular docking, DFT and antioxidant studies,” 2020, J. Mol. Struct., vol. 1208, p. 127905, doi: 10.1016/j.molstruc.2020.127905.

[10] T. Nawaz, A. Tajammal, and A. W. Qurashi, “Chalcones as Broad-Spectrum Antimicrobial Agents: A Comprehensive Review and Analysis of Their Antimicrobial Activities,” Dec. 2023, ChemistrySelect, vol. 8, no. 45, p. e202302798, doi: 10.1002/slct.202302798.

[11] S. Adhikari, P. Nath, V. K. Deb, N. Das, A. Banerjee, S. Pathak, and A. K. Duttaroy, “Pharmacological potential of natural chalcones: a recent studies and future perspective,” 2025, Front.Pharmacol, vol 16. doi: 10.3389/fphar.2025.1570385.

[12] P. Sekar, S. K. Raju, A. Velnayagam, and S. Somasundharam., “Structure-Activity Relationship (SAR) Studies of Chalcone-Based Molecules with Antimicrobial Activity,” 2025, IJPCAT, vol 1, no 4, pp. 94–107, Aug. doi: 10.64062/ijpcat.vol1.issue4.8.

[13] M. A. R. Garcia., “Chalcones as a Strategy against Bacterial Resistance: Structural Modifications and Mechanisms of Action in the Last Decade,” 2026, Current Bioactive Compounds, Vol. 22. doi: 10.2174/0115734072414740251118111210.

[14] C. Tratrat, M. Haroun, I. Xenikakis, K. Liaras, E. Tsolaki, P. Eleftheriou, a. Petrou, B. Aldhubiab, M. Attimarad, K. N. Venugopala, S. Harsha, H. S. Elsewedy, A. Geronikaki, M. Soković., “Design Synthesis, Evaluation of Antimicrobial Activity and Docking Studies of New Thiazole-based Chalcones,” 2019, Current Topic in Medicinal Chemistry, Vol 19, No. 5. doi: 10.2174/1568026619666190129121933.

[15] P. P. Gogoi, M. Pucho, P. Jamir, N. Boruah, B. Singha, P. Longkumer, B. Dkhar, I. Lytan, and U. B. Sinha., “Chalcones as Emerging Antibacterial Scaffolds: A Mini Review, Mini-Reviews.” 2025, Medicinal Chemistry, Vol 25, No. 19. doi: 10.2174/0113895575414987250918162246.

[16] M. Rudrapal, J. Khan, A. a. Dukhyil, R. M. I. I. Alarousy, E. I. Attah, T. Sharma, S. J. Khairnar, and A. R. Bendale, “Chalcone scaffolds, bioprecursors of flavonoids: Chemistry, bioactivities, and pharmacokinetics,” Dec. 01, 2021, Molecules. Vol 26, 7177. DOI: 10.3390/molecules26237177.

[17] W. Liu, Y. Feng, S. Yu, Z. Fan, X. Li, J. Li, and H. Yin., “The flavonoid biosynthesis network in plants,” Dec. 01, 2021, J. Mol. Sci. Vol. 22, 12824. doi: 10.3390/ijms222312824.

[18] J. A. Lewis, E. P. Jacobo, N. Palmer, W. Vemerris, S. E. Sattler, J. A. Brozik, G. Sarath, and C. Kang, “Structural and Interactional Analysis of the Flavonoid Pathway Proteins: Chalcone Synthase, Chalcone Isomerase and Chalcone Isomerase-like Protein,” 2024. Int. J. Mol. Sci., vol. 25, no. 11, doi: 10.3390/ijms25115651.

[19] T. Waki.R. Mameda, T. Nakano, S. Yamada, M. Terashita, K. Ito, N. Tenma, Y. Li, N. Fujino, K. Uno, S. Yamashita, Y. Aoki, K. Danessiouk, Y. Kawai, S. Sugawara, K. Saito, K. Y. Sakakibara, Y. Morita, A. Hoshino, S. Takahashi, and T. Nakayama, “A conserved strategy of chalcone isomerase-like protein to rectify promiscuous chalcone synthase specificity,” 2020, Nat. Commun., vol. 11, no. 1. doi: 10.1038/s41467-020-14558-9.

[20] T. T. H. Dao, H. J. M. Linthorst, and R. Verpoorte, “Chalcone synthase and its functions in plant resistance,” Sep. 2011, Phytochemistry Reviews, vol. 10, no. 3, pp. 397–412, doi: 10.1007/s11101-011-9211-7.

[21] J. F. Martín and P. Liras, “Comparative Molecular Mechanisms of Biosynthesis of Naringenin and Related Chalcones in Actinobacteria and Plants: Relevance for the Obtention of Potent Bioactive Metabolites,” Jan. 01, 2022, Antibiotic, Vol 11, No. 82. doi: 10.3390/antibiotics11010082.

[22] N. A. A. Elkanzi, H. Hrichi, R. A. Alolayan, W. Derafa, F. M. Zahou, and R. B. Bakr, “Synthesis of Chalcones Derivatives and Their Biological Activities: A Review,” Aug. 16, 2022, ACS Omega, Vol. 7, pp 27769-27786. doi: 10.1021/acsomega.2c01779.

[23] K. Goyal, R. Kaur, A. Goyal, and R. Awasthi, “Chalcones: A review on synthesis and pharmacological activities,” 2021, J. Appl. Pharm. Sci., vol. 11, no. Supplement 1, pp. 1–14, Mar. doi: 10.7324/JAPS.2021.11s101.

[24] E. J. Diana, U. S. Kanchana, T. V. Mathew, and G. Anilkumar, “Recent developments in the metal catalysed cross-coupling reactions for the synthesis of the enone system of chalcones,” Dec. 01, 2020, Appl Organomet Chem, Vo. 34. doi: 10.1002/aoc.5987.

[25] P. E. More, B. P. Bandgar, and V. T. Kamble, “Zinc oxide as a regioselective and heterogeneous catalyst for the synthesis of chalcones at room temperature,” Oct. 2012, Catal. Commun., vol. 27, pp. 30–32. doi: 10.1016/j.catcom.2012.06.012.

[26] G. Rajendran et al., “Chalcone: A Promising Bioactive Scaffold in Medicinal Chemistry,” Oct. 01, 2022, Pharmaceutical, Vol. 25. doi: 10.3390/ph15101250.

[27] G. B. Souza, T. A. C. Santos, A. P. S. Silva, A. L. B.S. Barreiros, V. B. Nardelli, I. B. Siqueira, S. S. Dolabella, E. V. Costa, P. B. Alves, R. Scher, R. P. M. Fernandes., “Synthesis of chalcone derivatives by Claisen-Schmidt condensation and in vitro analyses of their antiprotozoal activities,” Apr. 2024, Nat. Prod. Res., vol. 38, no. 8, pp. 1326–1333. doi: 10.1080/14786419.2022.2140337.

[28] L. Tedesco, F. Verdini, E. C. Gaudino, S. Tabasso, I. Arduino, D. Lembo, M. Donalisio, G. Cravotto, and M. Manzoli., “Sustainable route to antiviral furano-chalcones via microwave-assisted solvent-free synthesis with recyclable MgO,” Mar. 2026, Green Chem, Vol. 28. doi: 10.1039/d5gc06471f.

[29] P. T. B. Van, L. T. Huy, N. T. B. Thuy, V. T. Nga, L. M. Tam, H. Phuong, H. M. Hao., “Solvent-free, microwave-assisted, solid-catalyzed synthesis and α-Glucosidase inhibition of chalcones,” Jun. 2023, Vietnam J. Chemistry, vol. 61, no. 3, pp. 325–332. doi: 10.1002/vjch.202200151.

[30] O. Turani, M. J. Castro, J. Vazzana, P. Mendioroz, M. A. Volpe, D. C. Gerbino, and, C. Bouzat., “Potent Anthelmintic Activity of Chalcones Synthesized by an Effective Green Approach,” Jul. 2024, ChemMedChem, vol. 19, no. 13, doi: 10.1002/cmdc.202400071.

[31] F. Dong, C. Jian, F. Zhenghao, G. Kai, and L. Zuliang, “Synthesis of chalcones via Claisen-Schmidt condensation reaction catalyzed by acyclic acidic ionic liquids,” May 2008, Catal. Commun., vol. 9, no. 9, pp. 1924–1927, doi: 10.1016/j.catcom.2008.03.023.

[32] R. G. M. da Costa, F. R. L. Farias, D. Back, and J. Limberger, “Synthesis of arylated chalcone derivatives via palladium cross-coupling reactions,” 2018, Tetrahedron Lett., vol. 59, no. 8, pp. 771–775, doi: https://doi.org/10.1016/j.tetlet.2018.01.038.

[33] F. Otte, J. Greese, S. FoB, M. Kriiger, E. Sperlich, G. Kwesiga, and Bernd Schmidt., “Synthesis of Benzopyran-Phenylpropanoid Hybrids via Matsuda-Heck-Arylation and Allylic Oxidation,” 2018, J. Org. Chem, vol 89, pp. 18585-18601, doi: 10.1021/acs.joc.4c02520.

[34] L. C. C. Vieira, M. W. Paixão, and A. G. Corrêa, “Green synthesis of novel chalcone and coumarin derivatives via Suzuki coupling reaction,” May 2012, Tetrahedron Lett., vol. 53, no. 22, pp. 2715–2718, , doi: 10.1016/j.tetlet.2012.03.079.

[35] S. Narwal, S. Kumar, and P. K. Verma, “Synthesis and biological activity of new chalcone scaffolds as prospective antimicrobial agents,” 2021, Research on Chemical Intermediates, vol. 47, no. 4, pp. 1625–1641, doi: 10.1007/s11164-020-04359-6.

[36] L. S. Dhivya, B.K. Chagaleti, V. Saravanan et al., “Anti-Bacterial Activity of Furan Chalcone Derivatives Against Mycobacterium tuberculosis: Design, Synthesis, Anti-Bacterial Screening, Pharmacokinetic Properties, and Toxicity Parameters,” 2025, Curr. Microbiol., vol. 82, no. 8, p. 373, doi: 10.1007/s00284-025-04319-6.

[37] A. Thebti, A. Meddeb, I. B. Salem, C. Bakary, S. Ayari, F. Rezgui. K. E. Benkhadir, A. Boudabous, and H. I. Ouzari., “Antimicrobial Activities and Mode of Flavonoid Actions,” Feb. 2023, Antibiotics, vol. 12, no. 2, doi: 10.3390/antibiotics12020225.

[38] M. H. Nematollahi, M. Mehrabani, Y. Hozhabri, M. Mirtajaddini, and S. Iravani, “Antiviral and antimicrobial applications of chalcones and their derivatives: From nature to greener synthesis,” Oct. 01, 2023, Heliyon, vol. 9. doi: 10.1016/j.heliyon.2023.e20428.

[39] T. A. C. Santos, F. C. Sousa, A.P. Barreto, R. Scher, P.L. Assis, C. E. Vilaça, G.P. Roberto, R.P.M. Fernandes., “Methoxy Chalcone Derivatives: Promising Antimicrobial Agents Against Phytopathogens,” Nov. 2024, Chem. Biodivers., vol. 21, no. 11, p. e202400945, doi: https://doi.org/10.1002/cbdv.202400945.

[40] S. R. Baddam, M. K. Avula, R. Akula, V. R. Batulla, S. Kalagara, R. Buchikonda, S. Ganta, S. Vankatesan, and, T. R, Allaka., “Design, synthesis and in silico molecular docking evaluation of novel 1,2,3-triazole derivatives as potent antimicrobial agents,” Apr. 2024, Heliyon, vol. 10, no. 7, doi: 10.1016/j.heliyon.2024.e27773.

[41] S. Li and H. Jin, “Synthesis, Antibacterial Evaluation and Molecular Modeling of Novel Chalcone Derivatives Incorporating the Diphenyl Ether Moiety,” Molecules, vol. 30, no. 12, Jun. 2025, doi: 10.3390/molecules30122575.

[42] F. Akhter, S. S. Marufa, S. M. A. U. Shohag, H. Nishino, M. S. Alam, Md. A. Haque, and M. M. Rahman., “Synthesis, antimicrobial evaluation, ADMET prediction, molecular docking and dynamics studies of pyridine and thiophene moiety-containing chalcones,” Jan. 2025, R. Soc. Open Sci., vol. 12, no. 1, doi: 10.1098/rsos.241411.

[43] S. B. Lagu, R. P. Yejella, R. R. Bhandare, and A. B. Shaik, “Design, synthesis, and antibacterial and antifungal activities of novel trifluoromethyl and trifluoromethoxy substituted chalcone derivatives,” Nov. 2020, Pharmaceuticals, vol. 13, no. 11, pp. 1–16, doi: 10.3390/ph13110375.

[44] E. N. Okolo, D. I. Ugwu, B. E. Ezema, J. C. Ndefo, F. U. Eze, C. G. Ezema, J. A. Ezuguwu, and O. T. Ujam., “New chalcone derivatives as potential antimicrobial and antioxidant agent,” Dec. 2021, Sci. Rep., vol. 11, no. 1, doi: 10.1038/s41598-021-01292-5.

[45] S. Burmaoglu, O. Algul, A. Gobek, D. A. Anil, M. Ulger, B. G. E, E. Kaplan, A. Dogen, and G. Aslan., “Design of potent fluoro-substituted chalcones as antimicrobial agents,” Jan. 2017, J. Enzyme Inhib. Med. Chem., vol. 32, no. 1, pp. 490–495, doi: 10.1080/14756366.2016.1265517.

[46] Ö. F. Col and T. Tunc, “Synthesis, and in-vitro biological evaluation of chalcone derivatives as antimicrobial agents,” Dec. 2024, Bioorganic and Medicinal Chemistry Reports, no. 2, pp. 33–39, doi: 10.25135/bmcr.35.24.11.3365.

[47] S. Chen, M. Zhang, S. Feng, C. Gong, Y. Zhou, L. Xing, B. He, Y. Wu, and w. Xue., “Design, synthesis and biological activity of chalcone derivatives containing pyridazine,” Jul. 2023, Arabian Journal of Chemistry, vol. 16, no. 7, doi: 10.1016/j.arabjc.2023.104852.

[48] J. A. M. Al-Duraye, A. M. Abdula, and Y. Baqi, “New Chalcone Derivatives: Synthesis, Characterization, Antioxidant, Antimicrobial, and Docking Study Against GLcN-6-P Synthase,” Sep. 2025, Al-Mustansiriyah Journal of Science, vol. 36, no. 3, pp. 36–50, doi: 10.23851/mjs.v36i3.1702.

[49] A. Shaik, R. R. Bhandare, K. Palleapati, S. Nissankararao, V. Kancharlapalli, and S. Shaik, “Antimicrobial, antioxidant, and anticancer activities of some novel isoxazole ring containing chalcone and dihydropyrazole derivatives,” Feb. 2020, Molecules, vol. 25, no. 5doi: 10.3390/molecules25051047.

[50] A. Kumari and S. Kumar, “Synthesis, computational studies of new thymol derived chalcones and their benzotriazoles as antimicrobial agents,” Mar. 2025, Lett. Drug Des. Discov., vol. 22, no. 3, doi: 10.1016/j.lddd.2025.100029.

[51] I. S. Mahdi, A. M. Abdula, A. M. N. Jassim, and Y. Baqi, “Design, Synthesis, Antimicrobial Properties, and Molecular Docking of Novel Furan-Derived Chalcones and Their 3,5-Diaryl-∆2-pyrazoline Derivatives,” J an. 2024, Antibiotics, vol. 13, no. 1, doi: 10.3390/antibiotics13010021.

[52] P. Kumar, S. Saini, A. Gangwar, R. Sharma, and J. M. H. Anal, “Antibacterial activity of structurally diverse natural prenylated isobavachalcone derivatives,” Oct. 2024, RSC Adv., vol. 14, no. 45, pp. 32771–32785, doi: 10.1039/d4ra05370b.

[53] S. Cyboran-Mikołajczyk, K. Matczak, E. Olchowik-Grabarek, S. Sekowski, P. Nowicka, A. Krawczyk-Lebek, and E. Kostrzewa-Suslow., Aug. 2024, “The influence of the chlorine atom on the biological activity of 2′-hydroxychalcone in relation to the lipid phase of biological membranes - Anticancer and antimicrobial activity,” Chem. Biol. Interact., vol. 398, doi: 10.1016/j.cbi.2024.111082.

[54] M. H. Laiche and J. W. Barlow, “Recent Advances in the Synthesis and Biological Applications of Prenylated Chalcones,” Oct. 01, 2025, Int. J. Mol. Sci. doi: 10.3390/ijms26209845.

[55] S. Wang, C. Li, L. Zhang, B. Sun, Y. Cui, and F. Sang, “Isolation and biological activity of natural chalcones based on antibacterial mechanism classification,” Oct. 01, 2023, Bioor. Med. Chem. doi: 10.1016/j.bmc.2023.117454.

[56] S. Yang, G. Miao, X. Wang, F. Zhou, Z. Yuan, F. Wei, L. Ji, X. Wang, G. Dong, and Y. Wang., “Development of membrane-targeting chalcone derivatives as antibacterial agents against multidrug-resistant bacteria,” 2024, Eur. J. Med. Chem., vol. 280, p. 116969, doi: https://doi.org/10.1016/j.ejmech.2024.116969.

[57] A. Jesus, F. Duraes, N. Szemeredi, J. Freitas-Silva, P. M. da Costa, E. Pinto, M. Pinto, G. Spengler, E. Sousa, and H. CIdade., “BDDE-Inspired Chalcone Derivatives to Fight Bacterial and Fungal Infections,” May 2022, Mar. Drugs, vol. 20, no. 5, doi: 10.3390/md20050315.

[58] L. da Silva, I. A. Donato, S. R. Bezzera, H. S. dos Santos, N. Bandeira, M. T. R. do Nascimento, J. M Guedes et al., “Synthesis, spectroscopic characterization, and antibacterial activity of chalcone (2E)-1-(3′-aminophenyl)-3-(4-dimethylaminophenyl)-prop-2-en-1-one against multiresistant Staphylococcus aureus carrier of efflux pump mechanisms and β-lactamase,” Feb. 2024, Fundam. Clin. Pharmacol., vol. 38, no. 1, pp. 60–71, doi: 10.1111/fcp.12938.

[59] J. E. Rocha, T. S. de Freitas, J. C. Xavier, R. L.S Pereira, F. N. P. Junior, C. E. S. Nogueira, M. M. Marinho, P. N. Bandeira et al., “ADMET study, spectroscopic characterization and effect of synthetic nitro chalcone in combination with norfloxacin, ciprofloxacin, and ethidium bromide against Staphylococcus aureus efflux pumps,” Feb. 2023, Fundam. Clin. Pharmacol., vol. 37, no. 1, pp. 163–173, doi: 10.1111/fcp.12830.

[60] B. Ergüden, H. B. Lüleci, and Y. Ünver, “Chalcone Schiff bases disrupt cell membrane integrity of Saccharomyces cerevisiae and Candida albicans cells,” 2023, Arch. Microbiol., vol. 205, no. 6, p. 246, doi: 10.1007/s00203-023-03584-y.

[61] B. Ergüden and Y. Ünver, “Phenolic chalcones lead to ion leakage from Gram-positive bacteria prior to cell death,” 2021, Arch. Microbiol., vol. 204, no. 1, p. 3, doi: 10.1007/s00203-021-02603-0.

[62] S. Yang, G. Miao, X. Wang, F. Zhou, Z. Yuan, F. Wei, L. Ji, X. Wang, G. Dong, and Y. Wang., “Development of membrane-targeting chalcone derivatives as antibacterial agents against multidrug-resistant bacteria,” Dec. 2024, Eur. J. Med. Chem., vol. 280, doi: 10.1016/j.ejmech.2024.116969.

[63] L. R. de Assis, R. dS. Theodoro, M. B. S. Costa, J. A. S. Nascentes, M. D. da Rocha, M. A. dS. Bessa, R. dP. Menezes, G. Dilarri et al., “Antibacterial Activity of Isobavachalcone (IBC) Is Associated with Membrane Disruption,” Mar. 2022, Membranes (Basel)., vol. 12, no. 3, doi: 10.3390/membranes12030269.

[64] B. Zhang, Z. Teng, X. Li, X. Deng, X. Niu, and J. Wang., “Chalcone attenuates Staphylococcus aureus Virulence by Targeting Sortase A and Alpha-Hemolysin,” Sep. 2017, Front. Microbiol., vol. 8, 1715, doi: 10.3389/fmicb.2017.01715.

[65] H. H. Nima and A. H. Shntaif, “Synthesis of new pyrimidine derivatives and study their antibacterial activity: Computational and in vitro assessment,” 2025, Journal of Umm Al-Qura University for Applied Sciences, doi: 10.1007/s43994-025-00223-8.

[66] L. Feng, M. M. Maddox, Md. Z. Alam, L. S. Tsutsumi, G. Narula, D. F. Bruhn, X. Wu, S. Sandhaus, R. B. Lee et al., “Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives,” Oct. 2014, J. Med. Chem., vol. 57, no. 20, pp. 8398–8420, doi: 10.1021/jm500853v.

[67] M. Ayman, S. M. El-Messery, E. E. Habib, S. T. Al-Rashood, A. A. Almehizia, H. M. Alkahatani, and G. S. Hassan., “Targeting microbial resistance: Synthesis, antibacterial evaluation, DNA binding and modeling study of new chalcone-based dithiocarbamate derivatives,” 2019, Bioorg. Chem., vol. 85, pp. 282–292, doi: https://doi.org/10.1016/j.bioorg.2019.01.001.

[68] A. Mukherjee, S. Ghosh, S. Ghoosh, S. Mahato, M. Pal, S. K. S, A. Majee, and B. Singh., “Molecular recognition of synthesized halogenated chalcone by calf thymus DNA through multispectroscopic studies and analysis the anti-cancer, anti-bacterial activity of the compounds,” 2021, J. Mol. Liq., vol. 337, p. 116504, doi: https://doi.org/10.1016/j.molliq.2021.116504.

[69] I. Amalina, N. N. T. Puspaningsih, H. Suwito., “In silico analysis of chalcone derivatives as potential antibacterial agents against DHPS enzyme.” 2023, JATM, vol 2, no. 1, pp 16-21.

[70] S. H. Lee, A. Baiseitova, S. W. Moon, S. Y. Im, and K. H. Park, “Bacterial neuraminidase inhibitory chalcones from flowers of Coreopsis lanceolata, their kinetic characterization and antibiofilm effect,” 2024, Phytomedicine, vol. 130, p. 155789, doi: https://doi.org/10.1016/j.phymed.2024.155789.

[71] U. Tutar, U. M. Kocyigit, and H. Gezegen., “Evaluation of antimicrobial and carbonic anhydrase inhibition profiles of 1,3-bis-chalcone derivatives.” 2019, J. Biochem. Mol Toxicol, vol 33, no. 4, doi: 10.1002/jbt.22281.

[72] S. M. El-Messery, E. S. E. Habib, S. T. A. Al-Rashood, and G. S. Hassan, “Synthesis, antimicrobial, anti-biofilm evaluation, and molecular modelling study of new chalcone linked amines derivatives,” Jan. 2018, J. Enzyme Inhib. Med. Chem., vol. 33, no. 1, pp. 818–832, doi: 10.1080/14756366.2018.1461855.

[73] G. Hatamian, Z. S. Noghabi, A. Shakeri, G. Ebrahimipour, B. S. Fazly Bazzaz, and V. Soheili, “Chalcone derivatives against biofilm production of Streptococcus mutans by glucosyltransferase C inhibition,” 2025, Biochem. Biophys. Res. Commun., vol. 777, p. 152273, doi: 10.1016/j.bbrc.2025.152273.

[74] A. T. Lucas dos Santos, M. A. de Freitas, M. L. Q. da Silva, F. dos Santos Silva, A. G. dos Santos, A. V. S. Meneses, N. S. Farias, J. N. Pereira Carneiro et al., “In silico activity and effect of synthetic chalcones on Candida albicans and Candida tropicalis biofilms,” 2025, Biochimie, vol. 234, pp. 29–39, doi: https://doi.org/10.1016/j.biochi.2025.03.004.

[75] Y. Zhang, P. Bhasame, D. S. Reddy, D. Liu, Z. Yu, T. Zhao, Y. Zheng, A. Kumar, H. Yu, and L. Z. Ma., “Dual functions: A coumarin–chalcone conjugate inhibits cyclic-di-GMP and quorum-sensing signaling to reduce biofilm formation and virulence of pathogens,” Sep. 2023, mLife, vol. 2, no. 3, pp. 283–294, doi: 10.1002/mlf2.12087.

[76] C. D. Amengor, P. Gyan, P. D. Biniyam, C. Amaning-Danquah, B. K. Harley, V. Ohene-Adu, K. Adu-Adjei, B. M. Abudey, M. Osei, P. Quansah, C. M. Amengor, and L. S. Borquaye., “Substituted chalcones inhibit biofilm formation and efflux pumps of multidrug resistant Staphylococcus aureus: Antimicrobial, molecular docking, ADME and QSAR studies,” 2025, Bioorg. Chem., vol. 167, p. 109077, doi: 10.1016/j.bioorg.2025.109077.

[77] P. Negi, K. C. Pnada, M. Devi, D. Negi, S. Nimesh, S. K. Raul, S. Triphati., “Chalcone Hybrids: Potential Antimicrobial and Antioxidant Candidates,” 2024, Journal of Chemical Health Risks, vol. 14, no. 2.